<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698035</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF-067519</org_study_id>
    <nct_id>NCT00698035</nct_id>
  </id_info>
  <brief_title>Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients</brief_title>
  <acronym>E-String</acronym>
  <official_title>A Phase II Study of Vaginal Testosterone Cream vs. the ESTRING for Vaginal Dryness or Decreased Libido in Early Breast Cancer Patients Treated With Aromatase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to determine whether the ESTRING or a special
      preparation of a testosterone cream inserted vaginally are safe for use in breast cancer
      patients. This study will also evaluate if either of these treatments can improve symptoms of
      vaginal dryness or decreased sexual interest that are related to your treatment for breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a growing body of scientific literature to suggest that sexual functioning is one of
      the most distressing problems experienced by breast cancer survivors. Vaginal dryness,
      dyspareunia (pain during sexual intercourse), and decreased libido are common complaints
      among breast cancer patients. With increasing use of aromatase inhibitors which are
      associated with a higher rate of vaginal dryness than tamoxifen, these problems are becoming
      even more prominent. This study will evaluate the safety and tolerability of the ESTRING and
      1% testosterone cream administered vaginally as treatments for vaginal dryness and/or
      decreased libido in women receiving an aromatase inhibitor for early stage breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Persistently Elevated Serum Estradiol Level Outside the Post-menopausal Range</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Liquid chromatography tandem mass spectrometry (Quest Diagnostics). Persistently elevated serum estradiol level outside the post-menopausal range was defined as: Serum estradiol &gt;10 pg/dl on two consecutive collections at least 4 weeks apart. 2. If baseline estradiol was &gt;10 pg/dl, subsequent levels &gt;10 pg/ml higher than baseline were considered a significant elevation outside the post-menopausal range.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Estradiol (E2)</measure>
    <time_frame>12 weeks</time_frame>
    <description>serial measurements of serum estradiol (E2) by liquid chromatography tandem mass spectrometry (Quest Diagnostics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matched E2 by Commercial and Research (RIA) Analyses</measure>
    <time_frame>baseline, 4 weeks</time_frame>
    <description>Serum estradiol assays sent to the UCSF clinical laboratory are sent out to Quest Diagnostics, which uses LC/MS for their ultra-sensitive estradiol assay. Samples were also sent to a specialized research lab in England which has developed an ultrasensitive assay using radioimmunoassay (RIA) after ether extraction (sensitivity limit of 3pmol/l) to quantify low levels of estradiol found in post-menopausal women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Testosterone Levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>By serum ultrasensitive total testosterone test (Quest Diagnostics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Quality of Life</measure>
    <time_frame>Baseline, Week 4, Week 12</time_frame>
    <description>Cancer Rehabilitation Evaluation System (CARES) Sexual Dysfunction (SD) and Sexual Interest (SI) Subscales range from 0 to 4 and measure the severity of problems, with higher scores indicating more difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Satisfaction</measure>
    <time_frame>Baseline, Week 4, Week 12</time_frame>
    <description>Participants were asked to respond to a Sexual Satisfaction One Item Measure which asked &quot;Overall, how satisfactory to you is your sexual relationship with your partner?&quot; Response options range from 1 (Extremely unsatisfactory) to 6 (Extremely satisfactory).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vaginal Epithelium Scores</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>During a gynecologic exam, the vaginal epithelium was assessed by an examiner using the Vaginal Atrophy Scoring Scale to evaluate Rugae (lack of), Pallor (pinkness), Petechiae, Mucosal thinning, Dryness. Scores range from 0 (none) to 3 (severe); higher scores indicate less favorable outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Sexual Dysfunction, Physiological</condition>
  <arm_group>
    <arm_group_label>Testosterone Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estring 2mg ring inserted vaginally once every 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Cream</intervention_name>
    <description>1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
    <arm_group_label>Testosterone Cream</arm_group_label>
    <other_name>intravaginal testosterone cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estring</intervention_name>
    <description>2mg ring inserted vaginally once every 12 weeks</description>
    <arm_group_label>Estring</arm_group_label>
    <other_name>ESTRING Estrodial Vaginal Ring</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed Stage I-III breast cancer who are taking an
             aromatase inhibitor as adjuvant hormonal therapy. Patient must have started the
             aromatase inhibitor at least 60 days prior to enrolling.

          2. Postmenopausal estradiol levels at baseline as measured by standard laboratory
             analysis.

               -  Patient may be rendered postmenopausal through the use of a GnRH agonist, but
                  must have confirmed post-menopausal levels of serum estradiol on two lab tests at
                  least one month apart.

               -  If patient has been rendered post-menopausal by adjuvant chemotherapy but has had
                  a period within the past 12 months, post-menopausal levels of serum estradiol
                  must be documented on two lab tests at least 3 months apart.

          3. Age ≥18 and ≤80 years old.

          4. ECOG ≤1

          5. Adequate hematologic, hepatic, and renal function as defined by:

               -  Hgb ≥9 g/dL

               -  Absolute neutrophil count (ANC)/absolute granulocyte count (AGC) ≥1500 cells/mm3

               -  Platelet count ≥100,000/mm3

               -  Serum creatinine ≤1.5 mg/dL

               -  Total bilirubin ≤1.5 times the ULN; and aspartate aminotransferase ≤3 times the
                  ULN

          6. Normal thyroid function tested within the past 6 months (Patients with a diagnosis of
             hypothyroidism and on thyroid supplementation must have had thyroid function tests in
             the normal range within the past 3 months)

          7. Patient must have recovered from the side effects of previous chemotherapy, surgery,
             or radiation therapy for early breast cancer.

        Exclusion Criteria:

          1. History of radiation to the vaginal area

          2. Concurrent treatment with any type of oral, injectable or topical form of estrogen or
             androgen therapy including natural supplements marketed as hormone replacement
             products

          3. Initiation of topical moisturizers (for example, Replens), or herbal or alternative
             medicines to manage the symptoms of vaginal dryness while on study. Patients who were
             previously using these products may continue them with the same usage pattern while on
             study.

          4. Use of vaginal hormonal products (rings, inserts, creams, gels) containing estrogens
             or androgens within the past 30 days.

          5. History of an abnormal pap smear within the last 12 months

          6. History of endometrial or ovarian cancer

          7. Any episode of vaginal bleeding in the past 6 months that has not been evaluated by a
             gynecological exam and/or pelvic ultrasound

          8. History of sexual dysfunction prior to diagnosis of breast cancer ( Sexual dysfunction
             will be defined as loss of libido or inability to achieve orgasm for which patient
             sought medical attention or which patient felt significantly interfered with quality
             of life.)

          9. Moderate or severe depression for which the patient is receiving ongoing psychological
             counseling and/or taking antidepressants, and for whom, in the investigators opinion
             may be interfering in the patients sexual function independent of the side effects of
             breast cancer and aromatase inhibitor use.

         10. Use of any investigational agent for breast cancer within 3 weeks of study entry.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Melisko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2008</study_first_posted>
  <results_first_submitted>April 29, 2014</results_first_submitted>
  <results_first_submitted_qc>May 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2014</results_first_posted>
  <last_update_submitted>May 27, 2014</last_update_submitted>
  <last_update_submitted_qc>May 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaginal Testosterone Cream</keyword>
  <keyword>ESTRING</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunction, Physiological</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 76 enrolled participants, one participant consented and was assigned to ESTRING, but did not insert ESTRING prior to withdrawing from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Estring</title>
          <description>Estring 2mg ring inserted vaginally once every 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Testosterone Cream</title>
          <description>Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics for 75 participants who initiated treatment. One participant consented and was assigned to ESTRING, but did not insert ESTRING prior to withdrawing from the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Estring</title>
          <description>Estring 2mg ring inserted vaginally once every 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Testosterone Cream</title>
          <description>Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="37" upper_limit="78"/>
                    <measurement group_id="B2" value="57" lower_limit="38" upper_limit="74"/>
                    <measurement group_id="B3" value="56" lower_limit="37" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Serum Estradiol (E2)</title>
        <description>serial measurements of serum estradiol (E2) by liquid chromatography tandem mass spectrometry (Quest Diagnostics)</description>
        <time_frame>12 weeks</time_frame>
        <population>Per protocol, participants who completed 12 weeks of assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Estring</title>
            <description>Estring 2mg ring inserted vaginally once every 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Cream</title>
            <description>Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Estradiol (E2)</title>
          <description>serial measurements of serum estradiol (E2) by liquid chromatography tandem mass spectrometry (Quest Diagnostics)</description>
          <population>Per protocol, participants who completed 12 weeks of assigned treatment</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>E2 at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="36"/>
                    <measurement group_id="O2" value="9" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E2 at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="5"/>
                    <measurement group_id="O2" value="10" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E2 at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="12"/>
                    <measurement group_id="O2" value="8" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matched E2 by Commercial and Research (RIA) Analyses</title>
        <description>Serum estradiol assays sent to the UCSF clinical laboratory are sent out to Quest Diagnostics, which uses LC/MS for their ultra-sensitive estradiol assay. Samples were also sent to a specialized research lab in England which has developed an ultrasensitive assay using radioimmunoassay (RIA) after ether extraction (sensitivity limit of 3pmol/l) to quantify low levels of estradiol found in post-menopausal women</description>
        <time_frame>baseline, 4 weeks</time_frame>
        <population>Patients from both study arms arms with matched pairs of baseline and week 4 E2 performed by both commercial and research labs</population>
        <group_list>
          <group group_id="O1">
            <title>E2 by LC/MS</title>
            <description>A commercially available ultrasensitive E2 level was measured at baseline and 4 weeks (Quest Diagnostics, liquid chromatography tandem mass spectrometry (LC/MS, PM range &lt;10 pg/ml)</description>
          </group>
          <group group_id="O2">
            <title>E2 by RIA</title>
            <description>Additional measurement of baseline and week 4 E2 by RIA</description>
          </group>
        </group_list>
        <measure>
          <title>Matched E2 by Commercial and Research (RIA) Analyses</title>
          <description>Serum estradiol assays sent to the UCSF clinical laboratory are sent out to Quest Diagnostics, which uses LC/MS for their ultra-sensitive estradiol assay. Samples were also sent to a specialized research lab in England which has developed an ultrasensitive assay using radioimmunoassay (RIA) after ether extraction (sensitivity limit of 3pmol/l) to quantify low levels of estradiol found in post-menopausal women</description>
          <population>Patients from both study arms arms with matched pairs of baseline and week 4 E2 performed by both commercial and research labs</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline E2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="28.5"/>
                    <measurement group_id="O2" value="17.9" spread="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-week E2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="15.0"/>
                    <measurement group_id="O2" value="2.9" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of baseline estradiol between LC/MS and RIA</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Significant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of week 4 estradiol between LC/MS and RIA</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>singificant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Persistently Elevated Serum Estradiol Level Outside the Post-menopausal Range</title>
        <description>Liquid chromatography tandem mass spectrometry (Quest Diagnostics). Persistently elevated serum estradiol level outside the post-menopausal range was defined as: Serum estradiol &gt;10 pg/dl on two consecutive collections at least 4 weeks apart. 2. If baseline estradiol was &gt;10 pg/dl, subsequent levels &gt;10 pg/ml higher than baseline were considered a significant elevation outside the post-menopausal range.</description>
        <time_frame>12 Weeks</time_frame>
        <population>Per protocol, to be considered evaluable for the Primary Outcome, patients must complete both baseline evaluation and week 4 safety blood draw. 1 participant in the Testosterone arm was not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Estring</title>
            <description>Estring 2mg ring inserted vaginally once every 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Cream</title>
            <description>Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Persistently Elevated Serum Estradiol Level Outside the Post-menopausal Range</title>
          <description>Liquid chromatography tandem mass spectrometry (Quest Diagnostics). Persistently elevated serum estradiol level outside the post-menopausal range was defined as: Serum estradiol &gt;10 pg/dl on two consecutive collections at least 4 weeks apart. 2. If baseline estradiol was &gt;10 pg/dl, subsequent levels &gt;10 pg/ml higher than baseline were considered a significant elevation outside the post-menopausal range.</description>
          <population>Per protocol, to be considered evaluable for the Primary Outcome, patients must complete both baseline evaluation and week 4 safety blood draw. 1 participant in the Testosterone arm was not evaluable.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Testosterone Levels</title>
        <description>By serum ultrasensitive total testosterone test (Quest Diagnostics)</description>
        <time_frame>12 weeks</time_frame>
        <population>Per protocol, participants assigned to the Testosterone arm who completed 12 weeks of assigned treatment and had testosterone measurement at baseline, 4 weeks and 12 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Cream</title>
            <description>Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Total Testosterone Levels</title>
          <description>By serum ultrasensitive total testosterone test (Quest Diagnostics)</description>
          <population>Per protocol, participants assigned to the Testosterone arm who completed 12 weeks of assigned treatment and had testosterone measurement at baseline, 4 weeks and 12 weeks.</population>
          <units>ng/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testosterone at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" spread="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testosterone at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171" spread="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Quality of Life</title>
        <description>Cancer Rehabilitation Evaluation System (CARES) Sexual Dysfunction (SD) and Sexual Interest (SI) Subscales range from 0 to 4 and measure the severity of problems, with higher scores indicating more difficulty.</description>
        <time_frame>Baseline, Week 4, Week 12</time_frame>
        <population>Participants who provided responses to SD, SI and SS at 3 time points: Baseline (BL), Week 4 (W4), and Week 12 (W12)</population>
        <group_list>
          <group group_id="O1">
            <title>Estring</title>
            <description>Estring 2mg ring inserted vaginally once every 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Cream</title>
            <description>Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Quality of Life</title>
          <description>Cancer Rehabilitation Evaluation System (CARES) Sexual Dysfunction (SD) and Sexual Interest (SI) Subscales range from 0 to 4 and measure the severity of problems, with higher scores indicating more difficulty.</description>
          <population>Participants who provided responses to SD, SI and SS at 3 time points: Baseline (BL), Week 4 (W4), and Week 12 (W12)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SI (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.9"/>
                    <measurement group_id="O2" value="1.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SI (W4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.0"/>
                    <measurement group_id="O2" value="1.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SI (W12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.7"/>
                    <measurement group_id="O2" value="1.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.1"/>
                    <measurement group_id="O2" value="2.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD (W4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.1"/>
                    <measurement group_id="O2" value="2.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD (W12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.1"/>
                    <measurement group_id="O2" value="1.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in SI from BL to W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>Significant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in SD from BL to W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in SI from BL to W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0228</p_value>
            <p_value_desc>Significant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in SD from BL to W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Satisfaction</title>
        <description>Participants were asked to respond to a Sexual Satisfaction One Item Measure which asked &quot;Overall, how satisfactory to you is your sexual relationship with your partner?&quot; Response options range from 1 (Extremely unsatisfactory) to 6 (Extremely satisfactory).</description>
        <time_frame>Baseline, Week 4, Week 12</time_frame>
        <population>Participants who provided responses to SD, SI and SS at all 3 time points: Baseline (BL), Week 4 (W4), and Week 12 (W12)</population>
        <group_list>
          <group group_id="O1">
            <title>Estring</title>
            <description>Estring 2mg ring inserted vaginally once every 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Cream</title>
            <description>Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Satisfaction</title>
          <description>Participants were asked to respond to a Sexual Satisfaction One Item Measure which asked &quot;Overall, how satisfactory to you is your sexual relationship with your partner?&quot; Response options range from 1 (Extremely unsatisfactory) to 6 (Extremely satisfactory).</description>
          <population>Participants who provided responses to SD, SI and SS at all 3 time points: Baseline (BL), Week 4 (W4), and Week 12 (W12)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SS (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.6"/>
                    <measurement group_id="O2" value="3.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SS (W4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.8"/>
                    <measurement group_id="O2" value="3.7" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SS (W12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.5"/>
                    <measurement group_id="O2" value="4.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in SS from Baseline to Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Significant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in SS from Baseline to Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.139</p_value>
            <p_value_desc>Significant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vaginal Epithelium Scores</title>
        <description>During a gynecologic exam, the vaginal epithelium was assessed by an examiner using the Vaginal Atrophy Scoring Scale to evaluate Rugae (lack of), Pallor (pinkness), Petechiae, Mucosal thinning, Dryness. Scores range from 0 (none) to 3 (severe); higher scores indicate less favorable outcomes.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Patients with both baseline and week 12 gynecologic exams for evaluation of vaginal atrophy</population>
        <group_list>
          <group group_id="O1">
            <title>Estring</title>
            <description>Estring 2mg ring inserted vaginally once every 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Cream</title>
            <description>Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vaginal Epithelium Scores</title>
          <description>During a gynecologic exam, the vaginal epithelium was assessed by an examiner using the Vaginal Atrophy Scoring Scale to evaluate Rugae (lack of), Pallor (pinkness), Petechiae, Mucosal thinning, Dryness. Scores range from 0 (none) to 3 (severe); higher scores indicate less favorable outcomes.</description>
          <population>Patients with both baseline and week 12 gynecologic exams for evaluation of vaginal atrophy</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rugae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="0.80"/>
                    <measurement group_id="O2" value="-0.71" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.84"/>
                    <measurement group_id="O2" value="-0.91" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Petechiae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.07"/>
                    <measurement group_id="O2" value="-0.74" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal thinning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.49"/>
                    <measurement group_id="O2" value="-0.88" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="0.80"/>
                    <measurement group_id="O2" value="-0.71" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Differences in rugae, pallor, petechiae, mucosal thinning and dryness between baseline and week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Differences in rugae, pallor, mucosal thinning, and dryness from baseline to 12 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in petechiae between baseline and week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0061</p_value>
            <p_value_desc>Significant at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Estring</title>
          <description>Estring 2mg ring inserted vaginally once every 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Testosterone Cream</title>
          <description>Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vaginal itching or irritation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vaginal odor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Facial hair growth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michelle Melisko, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-353-7070</phone>
      <email>mmelisko@medicine.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

